Literature DB >> 32352894

Coxsackievirus B4 Exposure Results in Variable Pattern Recognition Response in the Kidneys of Female Non-Obese Diabetic Mice Before Establishment of Diabetes.

Debra L Walter1,2, Sarah E Benner1,2, Rosemary J Oaks3,4, Jean R Thuma5,6, Ramiro Malgor1,4,6, Frank L Schwartz5,6, Karen T Coschigano1,4,6, Kelly D McCall1,2,4,5,6.   

Abstract

End-stage renal disease (ESRD) is described by four primary diagnoses, diabetes, hypertension, glomerulonephritis, and cystic kidney disease, all of which have viruses implicated as causative agents. Enteroviruses, such as coxsackievirus (CV), are a common genus of viruses that have been implicated in both diabetes and cystic kidney disease; however, little is known about how CVs cause kidney injury and ESRD or predispose individuals with a genetic susceptibility to type 1 diabetes (T1D) to kidney injury. This study evaluated kidney injury resulting from coxsackievirus B4 (CVB4) inoculation of non-obese diabetic (NOD) mice to glean a better understanding of how viral exposure may predispose individuals with a genetic susceptibility to T1D to kidney injury. The objectives were to assess acute and chronic kidney damage in CVB4-inoculated NOD mice without diabetes. Results indicated the presence of CVB4 RNA in the kidney for at least 14 days post-CVB4 inoculation and a coordinated pattern recognition receptor response, but the absence of an immune response or cytotoxicity. CVB4-inoculated NOD mice also had a higher propensity to develop an increase in mesangial area 17 weeks post-CVB4 inoculation. These studies identified initial gene expression changes in the kidney resulting from CVB4 exposure that may predispose to ESRD. Thus, this study provides an initial characterization of kidney injury resulting from CVB4 inoculation of mice that are genetically susceptible to developing T1D that may one day provide better therapeutic options and predictive measures for patients who are at risk for developing kidney disease from T1D.

Entities:  

Keywords:  NOD; TLR3; coxsackievirus; kidney

Year:  2020        PMID: 32352894      PMCID: PMC7478222          DOI: 10.1089/vim.2019.0188

Source DB:  PubMed          Journal:  Viral Immunol        ISSN: 0882-8245            Impact factor:   2.257


  44 in total

1.  Diabetes acceleration or prevention by a coxsackievirus B4 infection: critical requirements for both interleukin-4 and gamma interferon.

Authors:  David V Serreze; Clive Wasserfall; Eric W Ottendorfer; Michael Stalvey; Melissa A Pierce; Charles Gauntt; Brian O'Donnell; James B Flanagan; Martha Campbell-Thompson; Tamir M Ellis; Mark A Atkinson
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

2.  Nephrotic syndrome in hand, foot and mouth disease caused by coxsackievirus A16: a case report.

Authors:  Hong-Tao Zhou; Bing Wang; Xiao-Yan Che
Journal:  Int J Infect Dis       Date:  2014-08-11       Impact factor: 3.623

3.  Experimental glomerulonephritis following successive inoculation of five different serotypes of group B coxsackieviruses in mice.

Authors:  M Isome; K Yoshida; S Suzuki; K Kume; J Suzuki; K Kato; H Suzuki
Journal:  Nephron       Date:  1997       Impact factor: 2.847

4.  Coxsackievirus B3 infection and type 1 diabetes development in NOD mice: insulitis determines susceptibility of pancreatic islets to virus infection.

Authors:  Kristen M Drescher; Ken Kono; Shubhada Bopegamage; Steven D Carson; Steven Tracy
Journal:  Virology       Date:  2004-11-24       Impact factor: 3.616

5.  Role of coxsackievirus B4 in the pathogenesis of acute glomerulonephritis.

Authors:  M Bayatpour; A Zbitnew; G Dempster; K R Miller
Journal:  Can Med Assoc J       Date:  1973-11-03       Impact factor: 8.262

6.  Concordance for type 1 (insulin-dependent) and type 2 (non-insulin-dependent) diabetes mellitus in a population-based cohort of twins in Finland.

Authors:  J Kaprio; J Tuomilehto; M Koskenvuo; K Romanov; A Reunanen; J Eriksson; J Stengård; Y A Kesäniemi
Journal:  Diabetologia       Date:  1992-11       Impact factor: 10.122

7.  Cellular and humoral immune responses in the early stages of diabetic nephropathy in NOD mice.

Authors:  Xiaoyan Xiao; Bin Ma; Baojun Dong; Peng Zhao; Ningwen Tai; Li Chen; F Susan Wong; Li Wen
Journal:  J Autoimmun       Date:  2009-02-05       Impact factor: 7.094

Review 8.  The pancreas in human type 1 diabetes: providing new answers to age-old questions.

Authors:  Mark A Atkinson; Roberto Gianani
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2009-08       Impact factor: 3.243

9.  Primer-BLAST: a tool to design target-specific primers for polymerase chain reaction.

Authors:  Jian Ye; George Coulouris; Irena Zaretskaya; Ioana Cutcutache; Steve Rozen; Thomas L Madden
Journal:  BMC Bioinformatics       Date:  2012-06-18       Impact factor: 3.169

10.  Phenylmethimazole suppresses dsRNA-induced cytotoxicity and inflammatory cytokines in murine pancreatic beta cells and blocks viral acceleration of type 1 diabetes in NOD mice.

Authors:  Kelly D McCall; Martin J Schmerr; Jean R Thuma; Calvin B L James; Maria C Courreges; Fabian Benencia; Ramiro Malgor; Frank L Schwartz
Journal:  Molecules       Date:  2013-03-27       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.